Summary
Illumina is laying off 96 employees at its San Diego headquarters as part of a restructuring plan. This follows previous job cuts and reflects broader cost-saving measures within the company. These layoffs are part of a larger trend in the medtech industry as companies grapple with profit pressures and changing market conditions.
Reliability and uptime matter in healthcare TrueNAS provides 24/7 support when it counts.
** Main Story**
Illumina Reduces San Diego Workforce Amidst Restructuring
Illumina, the renowned gene-sequencing giant, is reducing its workforce at its San Diego headquarters. The company will lay off 96 employees, according to official filings with the state of California. This news comes as Illumina navigates a complex landscape of geopolitical factors, increased competition, and a declining stock price, down approximately 35% year-to-date. These job cuts are not an isolated incident but rather a continuation of cost-cutting measures implemented by the company.
Layoffs Reflect a Broader Trend in the Medtech Industry
Illumina’s workforce reduction is a reflection of broader cost-saving initiatives within the company and echoes similar actions taken across the medtech industry. Companies like Staar Surgical and Thermo Fisher Scientific have also recently announced layoffs, indicating an industry-wide trend of workforce adjustments. A MedTech Dive analysis even documented over 14,000 layoffs in the medtech sector between January 2023 and mid-2024. This wave of job cuts underscores the challenges medtech companies face, including profit pressures and evolving strategic priorities.
Illumina’s Cost-Cutting Measures
The recent layoffs at Illumina’s San Diego headquarters follow a pattern of workforce reductions for the company. Earlier job cuts occurred between October 2024 and January 2025, affecting 49 employees, and in March 2024, affecting 111 employees. These actions form part of a wider effort to streamline operations and improve profitability under CEO Jacob Thaysen. Thaysen assumed leadership in September 2023 following a period of leadership challenges and the controversial acquisition of Grail.
The Grail Acquisition and Its Aftermath
The acquisition of Grail, a cancer test maker, proved to be a costly endeavor for Illumina, leading to legal battles with antitrust regulators and opposition from activist investor Carl Icahn. Icahn’s intervention led to a proxy fight, ultimately resulting in the departure of Illumina’s board chair and the resignation of former CEO Francis deSouza. Illumina eventually spun off Grail in June 2024 due to regulatory pressure.
Illumina’s Strategic Restructuring
Illumina’s current CEO, Jacob Thaysen, has overseen a period of restructuring and cost-cutting at the company. He informed investors earlier this year that Illumina had reduced its global workforce by approximately 12% over the past year in an effort to improve margins and drive revenue growth. The current layoffs impact various roles, including scientists, engineers, managers, analysts, and technicians.
Looking Ahead
As of the end of 2024, Illumina’s workforce comprised about 8,970 full-time employees and 60 part-time employees, excluding Grail. This represents a decrease from approximately 9,250 full-time employees in the previous year. As Illumina moves forward, its focus will likely remain on streamlining operations, pursuing strategic investments, and adapting to the dynamic medtech landscape. The company’s continued success will depend on its ability to navigate these challenges and capitalize on opportunities in the evolving genomics market. As of today, March 7, 2025, this information is current, but the situation remains fluid and may change.
Be the first to comment